Ublituximab
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by 188.221.143.48 (talk) at 21:08, 18 November 2012 (CD20 is the most widely used and best recognised of the many synonyms which are mentioned in the WHO document; MS4A1 page redirects to CD20 page; MS4A1 is the gene name and the antigen is widely called CD20 - the antibody recognises this antigen). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 21:08, 18 November 2012 by 188.221.143.48 (talk) (CD20 is the most widely used and best recognised of the many synonyms which are mentioned in the WHO document; MS4A1 page redirects to CD20 page; MS4A1 is the gene name and the antigen is widely called CD20 - the antibody recognises this antigen)
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | CD20 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
NY (what is this?) (verify) |
Ublituximab is an immunomodulator. It binds to CD20.[1]
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with changed CASNo identifier
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- All stub articles